Nocebo effects of Janus kinase inhibitors in the treatment of active ankylosing spondylitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Ho | - |
dc.contributor.author | Song, Gwan Gyu | - |
dc.date.accessioned | 2022-02-18T04:41:05Z | - |
dc.date.available | 2022-02-18T04:41:05Z | - |
dc.date.created | 2022-02-08 | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136183 | - |
dc.description.abstract | Ankylosing spondylitis (AS) is a chronic inflammatory condition associated with enthesis and inflammation of the spinal and sacroiliac joints, and it ultimately contributes to the erosion of bone and joints [1, 2, 3]. There is an unmet need to elucidate alternative modes of action to efficiently control AS, and this has led to the recent introduction of Janus kinase (JAK) inhibitors [4, 5, 6]. The nocebo effect, the negative equivalent of the placebo effect, refers to the adverse events (AEs) that arise after administration of an inactive drug with no active therapeutic advantage [7]. The nocebo effect is a factor relevant to the development of medications and the design of randomized controlled trials (RCTs) [8]. Significant nocebo effects can result in incorrect evaluation of treatment-related AEs because they increase the proportion of AEs in the placebo group or unrelated AEs in the patient group receiving active therapy [7]. These problems are particularly important because the nocebo effect is influenced by accumulated experience pertaining to a disease and is thought to be most marked in chronic diseases like AS where patients need multiple disease-management therapies [9]. We have examined possible discrepancies in the proportion of AEs between patients randomized to receive placebo and those randomized to receive the active comparator in randomized, placebo-controlled clinical trials involving JAK inhibitors for the treatment of AS [10, 11, 12]. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.subject | RHEUMATOID-ARTHRITIS | - |
dc.subject | DISEASE | - |
dc.title | Nocebo effects of Janus kinase inhibitors in the treatment of active ankylosing spondylitis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Young Ho | - |
dc.identifier.doi | 10.5414/CP203956 | - |
dc.identifier.scopusid | 2-s2.0-85117116593 | - |
dc.identifier.wosid | 000696260100005 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.59, no.10, pp.668 - 670 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 59 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 668 | - |
dc.citation.endPage | 670 | - |
dc.type.rims | ART | - |
dc.type.docType | Editorial Material | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | RHEUMATOID-ARTHRITIS | - |
dc.subject.keywordAuthor | JAK inhibitor | - |
dc.subject.keywordAuthor | Nocebo effect | - |
dc.subject.keywordAuthor | Placebo effect | - |
dc.subject.keywordAuthor | ankylosing spondilitis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.